Share on StockTwits

Equities researchers at Brean Capital raised their target price on shares of OHR Pharmaceutical (NASDAQ:OHRP) from $21.00 to $34.00 in a research report issued on Tuesday. The firm currently has a “buy” rating on the stock. Brean Capital’s target price points to a potential upside of 198.25% from the company’s current price.

OHR Pharmaceutical (NASDAQ:OHRP) traded down 1.75% during mid-day trading on Tuesday, hitting $11.20. 1,835,316 shares of the company’s stock traded hands. OHR Pharmaceutical has a 1-year low of $5.65 and a 1-year high of $20.00. The stock’s 50-day moving average is $8.72 and its 200-day moving average is $10.93. The company’s market cap is $264.5 million.

Ohr Pharmaceutical Inc (NASDAQ:OHRP) is a biotechnology rollup company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.